Editas Medicine, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

EDIT$2.51-8.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(amounts in thousands except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2023	81,767,263	$8	$1,580,241	$(1,231,350)	$198	$349,097
Exercise of stock options	23,809	—	193	—	—	193
Stock-based compensation expense	—	—	21,417	—	—	21,417
Vesting of restricted common stock awards	730,157	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	213,467	—	590	—	—	590
Unrealized gain on marketable debt securities	—	—	—	—	70	70
Net loss	—	—	—	(237,093)	—	(237,093)
Balance at December 31, 2024	82,734,696	$8	$1,602,441	$(1,468,443)	$268	$134,274
Issuance of common stock from at-the-market equity offering, net	14,327,365	2	42,846	—	—	42,848
Exercise of stock options	41,430	—	70	—	—	70
Stock-based compensation expense	—	—	10,000	—	—	10,000
Vesting of restricted common stock awards	476,731	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	286,774	—	424	—	—	424
Unrealized loss on marketable debt securities	—	—	—	—	(268)	(268)
Net loss	—	—	—	(160,060)	—	(160,060)
Balance at December 31, 2025	97,866,996	$10	$1,655,781	$(1,628,503)	$—	$27,288

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.